Leuthold Group LLC Makes New $7.90 Million Investment in Elevance Health, Inc. $ELV

Posted by George Bondi on May 17th, 2026

Leuthold Group LLC bought a new position in shares of Elevance Health, Inc. (NYSE:ELV – Free Report) during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 22,531 shares of the company’s stock, valued at approximately $7,898,000.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Sound View Wealth Advisors Group LLC boosted its stake in Elevance Health by 3.0% during the 4th quarter. Sound View Wealth Advisors Group LLC now owns 1,011 shares of the company’s stock valued at $354,000 after purchasing an additional 29 shares during the period. Perigon Wealth Management LLC raised its position in shares of Elevance Health by 2.2% during the 4th quarter. Perigon Wealth Management LLC now owns 1,371 shares of the company’s stock worth $481,000 after buying an additional 29 shares in the last quarter. Fulton Breakefield Broenniman LLC raised its position in shares of Elevance Health by 3.6% during the 4th quarter. Fulton Breakefield Broenniman LLC now owns 825 shares of the company’s stock worth $289,000 after buying an additional 29 shares in the last quarter. Savvy Advisors Inc. raised its position in shares of Elevance Health by 3.2% during the 4th quarter. Savvy Advisors Inc. now owns 979 shares of the company’s stock worth $343,000 after buying an additional 30 shares in the last quarter. Finally, Detalus Advisors LLC raised its position in shares of Elevance Health by 1.8% during the 3rd quarter. Detalus Advisors LLC now owns 1,726 shares of the company’s stock worth $558,000 after buying an additional 31 shares in the last quarter. 89.24% of the stock is currently owned by institutional investors and hedge funds.

Elevance Health Stock Down 1.0%

NYSE ELV opened at $392.74 on Friday. The company has a debt-to-equity ratio of 0.70, a current ratio of 1.48 and a quick ratio of 1.48. The company’s 50 day simple moving average is $322.88 and its 200 day simple moving average is $334.02. Elevance Health, Inc. has a 12 month low of $273.71 and a 12 month high of $412.96. The company has a market capitalization of $85.29 billion, a P/E ratio of 16.71, a PEG ratio of 2.23 and a beta of 0.66.

Elevance Health (NYSE:ELV – Get Free Report) last released its earnings results on Wednesday, April 22nd. The company reported $12.58 EPS for the quarter, topping analysts’ consensus estimates of $10.74 by $1.84. Elevance Health had a net margin of 2.62% and a return on equity of 15.58%. The business had revenue of $49.49 billion for the quarter, compared to the consensus estimate of $48.21 billion. During the same period in the previous year, the firm earned $11.97 EPS. The business’s revenue for the quarter was up 1.5% on a year-over-year basis. Elevance Health has set its FY 2026 guidance at 19.850- EPS. Equities research analysts expect that Elevance Health, Inc. will post 26.79 earnings per share for the current fiscal year.

Elevance Health Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Thursday, June 25th. Investors of record on Wednesday, June 10th will be issued a $1.72 dividend. This represents a $6.88 dividend on an annualized basis and a dividend yield of 1.8%. The ex-dividend date is Wednesday, June 10th. Elevance Health’s payout ratio is presently 29.26%.

Wall Street Analysts Forecast Growth

A number of analysts have commented on the stock. Royal Bank Of Canada downgraded shares of Elevance Health from an “outperform” rating to a “sector perform” rating and set a $358.00 price target on the stock. in a research report on Tuesday, February 3rd. Leerink Partners set a $364.00 price target on shares of Elevance Health in a research report on Thursday, April 23rd. Guggenheim boosted their price target on shares of Elevance Health from $396.00 to $399.00 and gave the stock a “buy” rating in a research report on Friday, April 24th. Sanford C. Bernstein boosted their price target on shares of Elevance Health from $384.00 to $424.00 and gave the stock an “outperform” rating in a research report on Friday, April 24th. Finally, Jefferies Financial Group dropped their price target on shares of Elevance Health from $395.00 to $391.00 and set a “buy” rating on the stock in a research report on Monday, April 20th. Thirteen equities research analysts have rated the stock with a Buy rating and ten have assigned a Hold rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $384.58.

Read Our Latest Research Report on ELV

Elevance Health Profile

(Free Report)

Elevance Health, Inc (NYSE: ELV) is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company’s strategic focus on integrated health care and benefit delivery.

Elevance’s core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.

Institutional Ownership by Quarter for Elevance Health (NYSE:ELV)

Receive News & Ratings for Elevance Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Elevance Health and related companies with MarketBeat.com's FREE daily email newsletter.